Sercan Yilmaz

Sercan Yilmaz

Auto-generated profile, based on publicly available information

Sercan Yilmaz

Department of Urology, Gulhane Training and Research Hospital, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in World Journal of Urology
Verified
Journal Article
Closed access
PDF file
LTLutfi Tunc
Lutfi Tunc
SYSerdar Yalcin
Serdar Yalcin
EKEngin Kaya
Engin Kaya
EGEymen Gazel
Eymen Gazel
SYSercan Yılmaz
Sercan Yılmaz
TTTheodoros Tokas
Theodoros Tokas

22 January 2021 in International Journal of Urology
Verified
Journal Article
Closed access
PDF file
ACAdem Emrah Coguplugil
Adem Emrah Coguplugil
TETurgay Ebiloglu
Turgay Ebiloglu
SSSelcuk Sarikaya
Selcuk Sarikaya
SYSercan Yilmaz
Sercan Yilmaz
BTBahadir Topuz
Bahadir Topuz
MGMesut Gurdal
Mesut Gurdal

1 January 2020 in Urology Research and Practice
Verified
Journal Article
Closed access
SYSerdar Yalçın
Serdar Yalçın
SYSercan Yılmaz
Sercan Yılmaz
EGEymen Gazel
Eymen Gazel
EKEngin Kaya
Engin Kaya
TATahsin Batuhan Aydoğan
Tahsin Batuhan Aydoğan
LTLütfi Tunç
Lütfi Tunç
Objective: Holmium laser enucleation of the prostate (HoLEP) is an endourologic minimal invasive intervention of benign prostate hyperplasia (BPH). The interest on HoLEP is increasing in the literature. The aim of the present study was to evaluate the learning curve and our preliminary results. Material and methods: A retrospective analysis on 600 patients with BPH who underwent HoLEP between July 2015 and April 2019 was performed. Perioperative measures including enucleation efficiency (EE), morcellation efficiency (ME), and percentage of resected tissue weight (PRW) were recorded. Hospitalization time (HT) and catheterization time (CT) were measured. Functional outcomes, Clavien–Dindo classification complications, and continence status were assessed at 1-, 3-, and 6-month follow-up. Results: The mean age, prostate size, and prostate-specific antigen levels of the patients were 64.54 years, 91 g, and 4.54 ng/mL, respectively. There were 38.3% of patients with ≥100 g prostate size. The measured EE, ME, and PRW were 1.12 g/min, 4 g/min, and 72%, respectively. The mean HT and CT were 24.53 h and 21.50 h, respectively. Functional outcomes showed significant improvement at 1-, 3-, and 6-month follow-up. Intraoperative and postoperative complications were comparable with the literature. The most common perioperative complication was superficial bladder mucosal injury (n=8, 1.33%). Only one patient had persistent stress urinary incontinence at 6-month follow-up. Conclusion: As mentioned in the literature, HoLEP indications are independent from prostate size. Our results showed similarity with the literature on functional outcomes, complication rates, and continence status. With its superior results, our HoLEP series from Turkey supports that HoLEP will replace transurethral resection of the prostate as the known current gold standard. Cite this article as: Yalçın S, Yılmaz S, Gazel E, Kaya E, Aydoğan TB, Aybal HÇ, et al. Holmium laser enucleation of the prostate for the treatment of size-independent BPH: A single-center experience of 600 cases. Turk J Urol 2020; 46(3): 219-25.

1 February 2016 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
SUSami Uguz
Sami Uguz
SYSercan Yilmaz
Sercan Yilmaz
AGAli Guragac
Ali Guragac
BTBahadır Topuz
Bahadır Topuz
EAEmin Aydur
Emin Aydur


24 May 2021 in Andrologia
Verified
Journal Article
Open access
PDF file
EKEngin Kaya
Engin Kaya
SYSercan Yılmaz
Sercan Yılmaz
OAOnur Açıkgöz
Onur Açıkgöz
HAHalil Cagrı Aybal
Halil Cagrı Aybal
MYMehmet Yilmaz
Mehmet Yilmaz
LTLutfi Tunc
Lutfi Tunc
Recently, with the advancements in laser technology, Holmium laser enucleation of the prostate (HoLEP) and Thulium laser enucleation of the prostate (ThuLEP) have come to the fore in the surgical treatment of benign prostatic hyperplasia (BPH). We aimed to evaluate and compare the outcomes of HoLEP and ThuLEP in patients with >100 ml prostate volume. Patients who underwent HoLEP and ThuLEP between July 2017 and March 2020 were reviewed retrospectively. The patients were divided into two groups as HoLEP (Group 1, n = 121) and ThuLEP (Group 2, n = 104). Perioperative parameters, functional outcomes, continence status, intra and post-operative complications were compared between groups in the post-operative 1st and 6th month. No significant difference was found in terms of total laser energy (TLE), morcellation efficiency (ME), enucleated tissue weight (ETW), complication rates (CR) and continence status of patients between both groups (p > .05). In favour of ThuLEP group, there were statistically significant differences regarding total operation time (TOT), laser efficiency (LE), enucleation time (ET) and enucleation efficiency (EE) between groups (p ≤ .05). HoLEP and ThuLEP can be used safely and effectively in prostates larger than 100 ml.